Adial Pharmaceuticals (NASDAQ:ADIL) Posts Earnings Results, Misses Estimates By $0.20 EPS

Adial Pharmaceuticals (NASDAQ:ADIL) announced its quarterly earnings data on Tuesday. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.20), Zacks reports.

Adial Pharmaceuticals Trading Up 0.5 %

Shares of Adial Pharmaceuticals stock traded up $0.00 on Thursday, hitting $0.97. 159,639 shares of the company’s stock were exchanged, compared to its average volume of 3,723,645. Adial Pharmaceuticals has a 1 year low of $0.77 and a 1 year high of $4.46. The company has a 50-day simple moving average of $1.12 and a 200-day simple moving average of $1.40.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.